Drugs Made In America Acquisition DMAA Institutional Ownership

Updated Oct 5, 2026

Drugs Made in America Acquisition Corp. (NASDAQ:DMAA) was reported as a holding by 23 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Collectively, these holders controlled 38.60% of Drugs Made in America Acquisition's outstanding shares in Q2 2026, down from 72.70% in Q1 2026.
• Total shares held in DMAA fell 47.99% from Q1 2026; the number of holders fell 25.81% from Q2 2025.
• Among the 23 holders of Drugs Made in America Acquisition, 3 added to their positions, 15 reduced their stakes and 5 left their positions unchanged.
• Combined, institutional investors held 11.89Mn shares of DMAA as of Q2 2026, down 10.97Mn from the prior quarter and down 8.93Mn from a year earlier.
• Karpus Management, Inc. held the largest position in DMAA at 2.51Mn shares as of June 30, 2026, or 8.14% of shares outstanding.
• The biggest increases in DMAA positions during Q2 2026 came from Clear Street Group Inc. (+28.39K shares) and JPMorgan Chase & Co (+10 shares).
• The biggest cuts to DMAA positions during Q2 2026 came from First Trust Capital Management L.P. (-1.46Mn shares), Westchester Capital Management, LLC (-1.09Mn shares), Wolverine Asset Management LLC (-721.62K shares), Glazer Capital, LLC (-678.51K shares) and Aristeia Capital, L.L.C. (-531.72K shares).
• Per Business Quant data, the 10 largest holders of Drugs Made in America Acquisition at the end of Q2 2026 were Karpus Management, Inc. (2.51Mn shares), Mizuho Securities USA LLC (2Mn shares), Polar Asset Management Partners Inc. (1.15Mn shares), Glazer Capital, LLC (999.9K shares), Wolverine Asset Management LLC (832.09K shares), Highbridge Capital Management LLC (809.05K shares), First Trust Capital Management L.P. (786.46K shares), Heights Capital Management, Inc (648.08K shares), Westchester Capital Management, LLC (581.79K shares) and Clear Street Group Inc. (382.44K shares).